J Korean Diabetes.  2012 Mar;13(1):27-32. 10.4093/jkd.2012.13.1.27.

Measurement and Treatment Goal of Postprandial Hyperglycemia

Affiliations
  • 1Division of Endocrinology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Sungnam, Korea. imdrksk@chollian.net

Abstract

Poorly controlled diabetes is associated with development of various diabetic complications. Large controlled clinical trials have demonstrated that intensive glycemic control can significantly decrease the development and/or progression of microvascular complications of diabetes. Until recently, the goal of treatment in diabetic subjects has been reducing HbA1c level, with a strong emphasis on fasting plasma glucose. Although control of fasting hyperglycemia is necessary, that alone is not sufficient to obtain optimal glycemic control. Recently, a growing body of evidence has suggested that postprandial hyperglycemia has greater impact on diabetes complications than does average blood glucose as measured by HbA1c or fasting plasma glucose. This report briefly reviews the measurement and treatment goal of postprandial glucose.

Keyword

Complication; Diabetes mellitus; Hyperglycemia

MeSH Terms

Blood Glucose
Diabetes Complications
Diabetes Mellitus
Fasting
Glucose
Hyperglycemia
Plasma
Blood Glucose
Glucose

Figure

  • Fig. 1 Average glucose level vs. glucose variability. Will two patients with the same mean blood glucose level but very different glucose variability have similar HbA1c levels?

  • Fig. 2 Relative contributions of fasting and postprandial hyperglycemia to overall diurnal hyperglycemia over quintiles of HbA1c. Adapted from Monnier et al. Diabetes Care 2003;26:881-5 [16].


Reference

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329:977–986.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995. 28:103–117.
Article
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998. 352:837–853.
4. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006. 332:73–78.
Article
5. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998. 339:229–234.
Article
6. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005. 353:2643–2653.
Article
7. Hirsch IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med. 2005. 118:Suppl 5A. 21S–26S.
Article
8. ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008. 358:2560–2572.
9. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008. 358:2545–2559.
Article
10. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009. 360:129–139.
Article
11. The DECODE study group. European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999. 354:617–621.
12. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999. 22:920–924.
Article
13. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Framingham Off spring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002. 25:1845–1850.
14. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care. 1999. 22:1262–1265.
Article
15. De Vegt F, Dekker JM, Ruhé HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999. 42:926–931.
Article
16. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003. 26:881–885.
Article
17. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011. 34:Suppl 2. S120–S127.
18. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999. 22:233–240.
Article
19. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007. 116:151–157.
Article
20. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009. 52:415–424.
Article
21. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009. 32:381–386.
Article
22. NAVIGATOR Study Group. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. Effect of nategl inide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010. 362:1463–1476.
23. American Diabetes Association. Postprandial blood glucose. American Diabetes Association. Diabetes Care. 2001. 24:775–778.
24. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J. Guideline Development Group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis. 2008. 18:S17–S33.
Article
25. Standards of medical care in diabetes-2012. Diabetes Care. 2012. 35:Suppl 1. S11–S63.
26. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007. 13:Suppl 1. 1–68.
27. Global guideline for type 2 diabetes. International Diabetes Federation Task Force on Clinical Guidelines [Internet]. International Diabetes Federation. 2006. cited 2012 Feb 15. Brussels: International Diabetes Federation;Available from: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf.
28. Self-monitoring of blood glucose in non-insulin treated type 2 diabetes [Internet]. International Diabetes Federation. 2009. cited 2012 Feb 15. Brussels: International Diabetes Federation;Available from: http://www.idf.org/webdata/docs/SMBG_EN2.pdf.
29. Gerich JE, Odawara M, Terauchi Y. The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk. Curr Med Res Opin. 2007. 23:1791–1798.
Article
30. 2011 guideline for management of postmeal glucose in diabetes [Internet]. International Diabetes Federation. 2011. cited 2012 Feb 15. Brussels: International Diabetes Federation;Available from: http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf.
31. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Diabetes Association. 2008. cited 2012 Feb 15. Toronto: Canadian Diabetes Association;Available from: http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf.
Full Text Links
  • JKD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr